Future studies should explore whether PIKfyve inhibition enhances anti‐CD20 efficacy across diverse B‐cell lymphoma subtypes, including diffuse large B‐cell lymphoma (DLBCL). This evidence concerns the gene PIKFYVE and B-cell non-Hodgkin lymphoma.